SW
Therapeutic Areas
Biofrontera Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Ameluz® (BF-200 ALA) | Actinic Keratosis (AK) - Pharmacokinetics | N/A (Post-Approval Study) |
| Ameluz® | Actinic Keratosis | Approved |
| Xepi® | Impetigo | Approved |
Leadership Team at Biofrontera
PH
Prof. Hermann Luebbert, PhD
Chief Executive Officer & Chairman of the Board
FL
Fred Leffler
Chief Financial Officer
GJ
George Jones
Chief Commercial Officer
JL
Jon Lyons, PhD, MBA
Vice President of Scientific & Medical Affairs
JJ
John J. Borer III, J.D.
Board of Directors
BJ
Beth J. Hoffman, Ph.D.
Board of Directors
DH
Dr. Heikki Lanckriet
Board of Directors
KD
Kevin D. Weber
Board of Directors